Peptides are naturally occurring biological molecules that play a prominent role in important biological activities. There are extensive efforts have been taken in pharmaceutical research and development (R&D) to innovate new peptides for the treatment of chronic conditions. Over 7000 naturally occurring peptides have been identified in recent years, which have crucial roles in human physiology, including actions as neurotransmitters, hormones, ion channel ligands, and growth factors, amongst others.
Market leaders operating in the market have undertaken various organic growth strategies in the peptide therapeutics market. The peptide therapeutics market majorly consists of the players such Eli Lilly and Company, Amgen Inc., TEVA PHARMACEUTICAL INDUSTRIES LTD, Polypeptide Group, EVER Pharma GmbH, Bristol-Myers Squibb Company, Novo Nordisk A/S, Sanofi, AstraZeneca PLC, and Glaxosmithkline PLC amongst others. Several organic approaches, such as product launches, and expansion in the peptide therapeutics market, have resulted in the positive growth of the market. Product launches help the company to strengthen its product offering and the customer base, which allows the company to hold a strong position in the market. Similarly, utilizing expansion activities, it is easy to venture into untapped economies and use the opportunities being offered.
Eli Lilly and Company and Amgen Inc. -Notable Market Players in Peptide Therapeutics Market
The peptide therapeutics market is expected to witness considerable growth during the pandemic. Certain factors such as increased research & development activities and enormous growth in diagnostic testing for coronavirus is expected to have potential impact on market growth. In addition, emphasis on vaccine development across the globe is also estimated to offer lucrative opportunity for the market growth.
Below is the list of the growth strategies done by the players operating in the peptide therapeutics market:
|
Year |
News |
|
Dec-20 |
Eli Lilly and Company announced results of its tirzepatide drug candidate for the management of type-2 diabetes. According to the results, the product has shown its efficacy to reduce A1C and body weight in the type-2 diabetic patients. |
|
Dec-20 |
Novo Nordisk submitted a label extension application to the European Medicines Agency (EMA) for the existing marketing authorization for Ozempic, a once-weekly glucagon-like peptide-1 (GLP-1) analogue, to introduce a new dose of 2.0 mg. |
|
Jul-20 |
AstraZeneca will leverage ProteinQure’s expertise in computational methods and structure-based drug design to accelerate the research and development of peptide therapeutics. |
|
Jul-19 |
Ambrx Inc. received a milestone payment from Bristol-Myers Squibb Company (“BMS”) to initiate a phase I clinical trial of long-acting Relaxin (peptide hormone) for the treatment of heart failure. |
